Buyback yield (TTM)
0.08%
Shareholder yield (TTM)
4.17%
5Y share count change
-9.6%
Buyback spend (TTM)
$98M
Cumulative buybacks
$47.7B
Key takeaways
- Bristol-Myers Squibb (BMY) repurchased about $98M of stock over the trailing twelve months.
- Diluted share count is down 9.6% over the last ~5 fiscal years — buybacks are net-shrinking the share base.
- TTM buyback ÷ stock-based-comp ratio of 0.18× — repurchases only partially offset SBC dilution.
- Cash buyback spend has compounded at -100.0% per year over the latest 5-year window.
- TTM repurchases used about 1% of free cash flow remaining after dividends.
Dividend & buyback yield over time for Bristol-Myers Squibb (BMY)
Stacked annual yields — buyback yield (TTM cash repurchases ÷ market cap) plus dividend yield from the same fiscal-year-end key-metrics period — show how total cash return per dollar of equity has evolved.
Diluted vs basic shares (annual) for Bristol-Myers Squibb (BMY)
Diluted weighted-average shares are the EPS denominator — a falling count means buybacks are outpacing SBC dilution.
Year-over-year change in diluted shares for Bristol-Myers Squibb (BMY)
Green is fewer shares vs the prior fiscal year (net repurchase); red is growth (dilution). The earliest year shown has no prior year to compare.
Cash buyback spend over time for Bristol-Myers Squibb (BMY)
Latest: $0.00
Overview
As of the 2025 fiscal year, Bristol-Myers Squibb (BMY) reported buyback spend of $0.00.
Through 2020–2025 (5 years), Bristol-Myers Squibb buyback spend delivered a -100.0% annualised rate; with a net decline across the window.
Bristol-Myers Squibb buyback spend peaked at $8B in 2022; the latest annual figure is $0.00 in 2025 (100.0% below peak).
The highest annual buyback spend of $8B was reported in 2022. The lowest in the available history was $0.00 in 2003.
Bristol-Myers Squibb Buyback Spend 2025: $0.00
Bristol-Myers Squibb buyback spend in 2025 was $0.00.
Bristol-Myers Squibb Buyback Spend 2024: $0.00
Bristol-Myers Squibb buyback spend in 2024 was $0.00, plunged 100.0% below 2023.
Bristol-Myers Squibb Buyback Spend 2023: $5.16B
2023's buyback spend for Bristol-Myers Squibb came in at $5.16B, plunged 35.6% below 2022.
Bristol-Myers Squibb Buyback Spend 2022: $8B
Bristol-Myers Squibb posted buyback spend of $8B in 2022, grew 27.3% from 2021. This figure represents the highest annual value in the available history.
Bristol-Myers Squibb Buyback Spend 2021: $6.29B
Bristol-Myers Squibb buyback spend in 2021 was $6.29B.
See more financial history for Bristol-Myers Squibb (BMY).
Buyback, SBC & dilution history
Buyback spend, SBC, net dilution effect, and share count.
| 2025 | $0.00 | $553M | -$553M | — | 2.04B | +0.7% | |
| 2024 | $0.00 | $507M | -$507M | — | 2.03B | -2.5% | |
| 2023 | $5.16B | $518M | $4.64B | 4.96% | 2.08B | -3.2% | |
| 2022 | $8B | $457M | $7.54B | 5.28% | 2.15B | -4.4% | |
| 2021 | $6.29B | $583M | $5.7B | 4.68% | 2.25B | -0.6% | |
| 2020 | $1.55B | $779M | $767M | 1.11% | 2.26B | +31.9% | |
| 2019 | $7.3B | $441M | $6.86B | 5.94% | 1.71B | +4.6% | |
| 2018 | $320M | $221M | $99M | 0.38% | 1.64B | -0.9% | |
| 2017 | $2.47B | $199M | $2.27B | 2.46% | 1.65B | -1.7% | |
| 2016 | $231M | $205M | $26M | 0.24% | 1.68B | +0.1% | |
| 2015 | $0.00 | $235M | -$235M | — | 1.68B | +0.5% | |
| 2014 | $0.00 | $213M | -$213M | — | 1.67B | +0.5% | |
| 2013 | $433M | $191M | $242M | 0.49% | 1.66B | -1.5% | |
| 2012 | $2.4B | $154M | $2.25B | 4.49% | 1.69B | -1.7% | |
| 2011 | $1.22B | $161M | $1.06B | 2.05% | 1.72B | -0.6% | |
| 2010 | $576M | $193M | $383M | 1.27% | 1.73B | -12.7% | |
| 2009 | $0.00 | $183M | -$183M | — | 1.98B | -1.1% | |
| 2008 | $0.00 | $181M | -$181M | — | 2B | +1.1% | |
| 2007 | $0.00 | $0.00 | $0.00 | — | 1.98B | +0.9% | |
| 2006 | $0.00 | $0.00 | $0.00 | — | 1.96B | -1.0% | |
| 2005 | $0.00 | $0.00 | $0.00 | — | 1.98B | +0.4% | |
| 2004 | $0.00 | $0.00 | $0.00 | — | 1.98B | +1.3% | |
| 2003 | $0.00 | $0.00 | $0.00 | — | 1.95B | -3.3% | |
| 2002 | $164M | $0.00 | $164M | 0.32% | 2.02B | +2.6% | |
| 2001 | $1.59B | $0.00 | $1.59B | 1.61% | 1.97B | -1.6% | |
| 2000 | $2.34B | $0.00 | $2.34B | — | 2B | -1.5% | |
| 1999 | $1.42B | $0.00 | $1.42B | — | 2.03B | -0.2% | |
| 1998 | $1.56B | $0.00 | $1.56B | — | 2.03B | -0.5% | |
| 1997 | $1.16B | $0.00 | $1.16B | — | 2.04B | +0.3% | |
| 1996 | $852M | $0.00 | $852M | — | 2.04B | — | |
| 1995 | $244M | $0.00 | $244M | — | — | — | |
| 1994 | $701M | $0.00 | $701M | — | — | — | |
| 1993 | $419M | $0.00 | $419M | — | — | — | |
| 1992 | $228M | $0.00 | $228M | — | — | — | |
| 1991 | $447M | $0.00 | $447M | — | — | — | |
| 1990 | $562M | $0.00 | $562M | — | — | — | |
| 1989 | $51M | $0.00 | $51M | — | — | — |
- 2025$0.00
- 2024$0.00
- 2023$5.16B
- 2022$8B
- 2021$6.29B
- 2020$1.55B
- 2019$7.3B
- 2018$320M
- 2017$2.47B
- 2016$231M
- 2015$0.00
- 2014$0.00
- 2013$433M
- 2012$2.4B
- 2011$1.22B
- 2010$576M
- 2009$0.00
- 2008$0.00
- 2007$0.00
- 2006$0.00
- 2005$0.00
- 2004$0.00
- 2003$0.00
- 2002$164M
- 2001$1.59B
- 2000$2.34B
- 1999$1.42B
- 1998$1.56B
- 1997$1.16B
- 1996$852M
- 1995$244M
- 1994$701M
- 1993$419M
- 1992$228M
- 1991$447M
- 1990$562M
- 1989$51M
Buybacks vs stock-based compensation for Bristol-Myers Squibb (BMY)
Annual cash repurchases set against stock-based compensation. Coverage above 1× means buybacks fully offset the equity dilution from SBC. TTM coverage: 0.18×.
Buybacks vs dividends (share of cash returned) for Bristol-Myers Squibb (BMY)
How Bristol-Myers Squibb splits cash returned to shareholders between dividends and buybacks.
Sector peers by buyback spend
Companies in the same sector as Bristol-Myers Squibb, ranked by their latest buyback spend.
| $5.95B | |
| $5.55B | |
| $5.08B | |
| $4.11B | |
| $3B | |
| $980M | |
| $216M | |
| $0.00 |
- $5.95B
- $5.55B
- $5.08B
- $4.11B
- $980M
- $216M
- $0.00
Buyback capacity (TTM)
Free cash flow minus dividends paid versus actual TTM repurchases — the headroom bar shows how much of post-dividend FCF is still being deployed elsewhere.
Headroom $6.84B (TTM FCF − TTM dividends, clamped at zero).
Frequently asked questions
Data & methodology
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
- Buybacks0.08% TTM
- Dividend Profile3.98% yield
- Dividend Calculator
- Dividend Forecast
- Dividend Capture
- Stock Split History6 splits
How this company returns cash to shareholders — buybacks, dividends, and stock splits.